Cancer Targeted Therapy
Cancer targeted therapy is the foundation of precision medicine; it uses drugs or other substances to target specific genes and proteins that control cancer cells’ growth, division and spreading. Compared to traditional chemotherapy drugs, targeted-drugs can specifically act on cancer cells with high efficacy without damaging normal cells. Drugs used in cancer targeted therapy mainly includes small molecules and macromolecules (e.g., monoclonal antibodies), which can target cancer cells and constituents in the tumor microenvironment to activate the immune system. Anti-angiogenesis drugs, such as those targeting vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor (TGF)-α, TGF-β, Tumor necrosis factor (TNF)-α, and platelet-derived endothelial growth factor (PDGFR) inhibit the proliferation and metastasis of cancer cells. In recent years, the proportion of antibody drugs in cancer treatment has gradually become prominent. Antibody-drug conjugates (ADCs) are a new type of targeted drugs that are composed of monoclonal antibody, cytotoxic drug and linker. ADCs can deliver drugs to tumor cells and minimize the toxicity to normal tissues. Proteolysis-targeting chimera (PROTAC) is a useful technology for targeted protein degradation. PROTAC exploits the ubiquitin-proteasome system and forms a ternary complex with a hijacked E3 ubiquitin ligase and target protein, leading to polyubiquitination and degradation of the target protein.
Targeted therapy is a useful strategy in treatment of cancer either alone or in combination with standard chemotherapy. At present, targeted therapy has proved significant clinical success in the treatment of many types of cancer, including breast cancer, colorectal cancer, leukemia, ovarian cancer and lung cancer.
-
Tetrahydrouridine (Standard)
0 ImagesCat. No.: HY-15345ARCAS No.: 18771-50-1Synonyms: THU (Standard); NSC-112907 (Standard)Tetrahydrouridine (Standard) is the analytical standard of Tetrahydrouridine. This product is intended for research and analytical applications. Tetrahydrouridine dihydrate is potent inhibitor of cytidine deaminase (CDA), which competitively blocks the enzyme's active site more effectively than intrinsic cytidine.
-
Avasimibe (Standard)
0 ImagesSynonyms: CI-1011 (Standard); PD-148515 (Standard)Avasimibe (Standard) is the analytical standard of Avasimibe. This product is intended for research and analytical applications. Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively. Avasimibe can be used for the research of prostate cancer.
-
P13I
0 ImagesCat. No.: HY-W591307CAS No.: 2360561-66-4P131 is a PROTAC molecule comprised of Pomalidomide-based cereblon ligand and IBT6A, linked by a PEG 3 chain. P131 can degrade both wild-type and C481S mutant BTK with nanomolar potencies.
-
Ibudilast (Standard)
0 ImagesSynonyms: KC-404 (Standard); AV-411 (Standard); MN-166 (Standard)Ibudilast (Standard) is the analytical standard of Ibudilast. This product is intended for research and analytical applications. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia.
-
Tubulin inhibitor 9
0 ImagesCat. No.: HY-137866CAS No.: 1151995-69-5Tubulin inhibitor 9 (compound 7) is a tubulin (Microtubule/Tubulin)Inhibitors with anticancer activity (MDA-MB 231, IC50=0.9 nM).
-
PIM1-IN-1 (Standard)
0 ImagesCat. No.: HY-111552RCAS No.: 1417630-95-5PIM1-IN-1 (Standard) is the analytical standard of PIM1-IN-1 (HY-111552). This product is intended for research and analytical applications. PIM1-IN-1 is a potent and highly selective PIM1/3 inhibitor, with IC50s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC50 of 262 nM. PIM1-IN-1 shows no obvious effect on FLT3 or hERG binding. Antiproliferative and anti-cancer activity.
-
MDM2-p53-IN-20
0 ImagesCat. No.: HY-161041CAS No.: 2095120-09-3MDM2-p53-IN-20 (Compd B-11j) is a synthetic MDM2-p53 interaction inhibitor that play an important role in cancer.
-
tert-Butyl ([1,4'-bipiperidin]-4-ylmethyl)carbamate
![tert-Butyl ([1,4'-bipiperidin]-4-ylmethyl)carbamate](https://file.medchemexpress.com/product_pic/hy-w791598.gif "Click to View tert-Butyl ([1,4'-bipiperidin]-4-ylmethyl)carbamate Product Detail")
0 ImagesCat. No.: HY-W791598CAS No.: 883512-84-3
-
Melanocin A
0 ImagesCat. No.: HY-N14240CAS No.: 670274-36-9Melanocin A is a Melanin biosynthesis inhibitor. Melanocin A inhibits the biosynthesis of melanin and tyrosinase (IC50 is 9.0 nM, MIC is 0.9 μM). Melanocin A also has antioxidant effect.
-
IDH-305 (Standard)
0 ImagesCat. No.: HY-104036RCAS No.: 1628805-46-8IDH-305 (Standard) is the analytical standard of IDH-305 (HY-104036). This product is intended for research and analytical applications. IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1 (R132) mutation. IDH-305 exhibits greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC50= 27 nM (IDH1R132H), 28 nM (IDH1R132C), 6.14 µM (IDH1WT)).
-
Tert-butyl 4-(cyanomethyl)piperazine-1-carboxylate
0 ImagesCat. No.: HY-W046507CAS No.: 77290-31-4
-
CRBN ligand-266
0 ImagesCat. No.: HY-W953170CAS No.: 2925088-32-8
-
(R)-CCG-1423
0 ImagesCat. No.: HY-158652CAS No.: 2309931-09-5(R)-CCG-1423 is an inhibitor of RhoA. (R)-CCG-1423 inhibits downstream of Rho and shows specificity for SRE.
-
Digallic acid
0 ImagesDigallic acid is an antioxidant, antimutagenic, antigenotoxic, and anti-hyperuricemic compound. Digallic acid is a reverse transcriptase and XOD, URAT1 (IC50: 5.34 μM) inhibitor. Digallic acid scavenges DPPH· and O2·− radicals. Digallic acid induces apoptosis. Digallic acid can be isolated from the fruits of Pistascia lentiscus.
-
Vecabrutinib (Standard)
0 ImagesCat. No.: HY-109078RCAS No.: 1510829-06-7Synonyms: SNS-062 (Standard)Vecabrutinib (Standard) is the analytical standard of Vecabrutinib (HY-109078). This product is intended for research and analytical applications. Vecabrutinib (SNS-062) is a potent, noncovalent BTK and ITK inhibitor, with Kd values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC50 of 24 nM for ITK.
-
PD-L1/HDAC-IN-1
0 ImagesCat. No.: HY-172167CAS No.: 2923313-69-1PD-L1/HDAC-IN-1 (Compound 14) is the inhibitor for PD-L1 and HDAC that inhibits PD-1/PD-L1 interaction, HDAC2 and HDAC3 with IC50 of 88.10, 27.98 and 14.47 nM, respectively. PD-L1/HDAC-IN-1 exhibits slight cytotoxicity in MCF-7 (IC50=19.34 μM). PD-L1/HDAC-IN-1 upregulates the expression of PD-L1 and CXCL10, promoting anti-tumour immune response by recruiting T-cell infiltration into TME.
-
Mal-PEG2-CH2COOH
0 ImagesMal-PEG2-CH2COOH is an ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
-
3-(4-Carboxyphenyl)propanoic acid
0 ImagesCat. No.: HY-20049CAS No.: 38628-51-2
